A Phase II Study of Biological Response to Dasatinib Treatment in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma.

Trial Profile

A Phase II Study of Biological Response to Dasatinib Treatment in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 19 Aug 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 15 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top